Director Clinical Development at Rare Thyroid Therapeutics - Stockholm, Stockholm County, Sweden
Rare Thyroid Therapeutics is a privately held pharmaceutical company, developing therapies for rare and neglected thyroid hormone disorders. Our lead product candidate Emcitate® is under development for the treatment of MCT8 deficiency, also called Allan-Herndon-Dudley Syndrome, a rare inborn X-linked disorder caused by a dysfunctional thyroid hormone transporter.